Media Summary: The full article for this interview is available on Oncology Data Advisor. Check it out here: ... Is it time to rethink the definition of “cure” for stage IV colorectal cancer? In this episode of BackTable Tumor Board, medical ... J. Randolph Hecht, MD, UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA, gives an overview of much-awaited ...

Clinic Conversation Checkmate 8hw Study - Detailed Analysis & Overview

The full article for this interview is available on Oncology Data Advisor. Check it out here: ... Is it time to rethink the definition of “cure” for stage IV colorectal cancer? In this episode of BackTable Tumor Board, medical ... J. Randolph Hecht, MD, UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA, gives an overview of much-awaited ... Sara Lonardi, MD, Veneto Institute of Oncology, Padua, Itay, discusses the Phase III John Strickler, MD, Duke University, Durham, NC, gives an overview of the Phase III Dr. Thierry André from Hôpital Saint-Antoine gives an overview of the

Sakti Chakrabarti, MD, University Hospitals Seidman Cancer Center, highlights new data from the BREAKWATER and ... Italy, discusses the health-related quality of life (HRQoL) outcomes from the Heinz-Josef Lenz, MD, FACP, University of Southern California, Los Angeles, CA, discusses expanded Michael Foote, MD, Memorial Sloan Kettering Cancer Center, discusses the final results from the

Photo Gallery

Clinic Conversation: CheckMate 8HW Study and the Future of Immunotherapy in Colorectal Cancer
Applying CheckMate 8HW: Practical Updates for MSI-High CRC w/ Dr. Cathy Eng | Ep. 75
Practice-changing CRC cancer trials at ASCO 2025: ATOMIC & CheckMate 8HW
CheckMate 8HW: HRQoL outcomes of nivolumab and ipilimumab in MSI-H/dMMR mCRC
CheckMate 8HW: nivolumab & ipilimumab in MSI-H/dMMR metastatic CRC
KEYNOTE-177 and CheckMate 8HW: promising first-Line immunotherapy for MSI-H mCRC
CheckMate 8HW: nivolumab and ipilimumab in MSI-H/dMMR mCRC
CheckMate 8HW from GI ASCO 2025 with Nivolumab/Ipilimumab in MSI-H Patients
CheckMate 8HW: Nivolumab Plus Ipilimumab Versus Chemotherapy for Metastatic Colorectal Cancer
Targeted and Immuno-Oncology Advances in mCRC: BREAKWATER, CheckMate 8HW, and CHALLENGE
HRQoL findings from CheckMate 8HW: nivolumab and ipilimumab in MSI-H/dMMR mCRC
CheckMate 8HW: expanded analysis of nivolumab & ipilimumab in MSI-H/dMMR mCRC
View Detailed Profile
Clinic Conversation: CheckMate 8HW Study and the Future of Immunotherapy in Colorectal Cancer

Clinic Conversation: CheckMate 8HW Study and the Future of Immunotherapy in Colorectal Cancer

The full article for this interview is available on Oncology Data Advisor. Check it out here: ...

Applying CheckMate 8HW: Practical Updates for MSI-High CRC w/ Dr. Cathy Eng | Ep. 75

Applying CheckMate 8HW: Practical Updates for MSI-High CRC w/ Dr. Cathy Eng | Ep. 75

Is it time to rethink the definition of “cure” for stage IV colorectal cancer? In this episode of BackTable Tumor Board, medical ...

Practice-changing CRC cancer trials at ASCO 2025: ATOMIC & CheckMate 8HW

Practice-changing CRC cancer trials at ASCO 2025: ATOMIC & CheckMate 8HW

J. Randolph Hecht, MD, UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA, gives an overview of much-awaited ...

CheckMate 8HW: HRQoL outcomes of nivolumab and ipilimumab in MSI-H/dMMR mCRC

CheckMate 8HW: HRQoL outcomes of nivolumab and ipilimumab in MSI-H/dMMR mCRC

...

CheckMate 8HW: nivolumab & ipilimumab in MSI-H/dMMR metastatic CRC

CheckMate 8HW: nivolumab & ipilimumab in MSI-H/dMMR metastatic CRC

Sara Lonardi, MD, Veneto Institute of Oncology, Padua, Itay, discusses the Phase III

KEYNOTE-177 and CheckMate 8HW: promising first-Line immunotherapy for MSI-H mCRC

KEYNOTE-177 and CheckMate 8HW: promising first-Line immunotherapy for MSI-H mCRC

Furthermore, the Phase III

CheckMate 8HW: nivolumab and ipilimumab in MSI-H/dMMR mCRC

CheckMate 8HW: nivolumab and ipilimumab in MSI-H/dMMR mCRC

John Strickler, MD, Duke University, Durham, NC, gives an overview of the Phase III

CheckMate 8HW from GI ASCO 2025 with Nivolumab/Ipilimumab in MSI-H Patients

CheckMate 8HW from GI ASCO 2025 with Nivolumab/Ipilimumab in MSI-H Patients

We delved into the

CheckMate 8HW: Nivolumab Plus Ipilimumab Versus Chemotherapy for Metastatic Colorectal Cancer

CheckMate 8HW: Nivolumab Plus Ipilimumab Versus Chemotherapy for Metastatic Colorectal Cancer

Dr. Thierry André from Hôpital Saint-Antoine gives an overview of the

Targeted and Immuno-Oncology Advances in mCRC: BREAKWATER, CheckMate 8HW, and CHALLENGE

Targeted and Immuno-Oncology Advances in mCRC: BREAKWATER, CheckMate 8HW, and CHALLENGE

Sakti Chakrabarti, MD, University Hospitals Seidman Cancer Center, highlights new data from the BREAKWATER and

HRQoL findings from CheckMate 8HW: nivolumab and ipilimumab in MSI-H/dMMR mCRC

HRQoL findings from CheckMate 8HW: nivolumab and ipilimumab in MSI-H/dMMR mCRC

... Italy, discusses the health-related quality of life (HRQoL) outcomes from the

CheckMate 8HW: expanded analysis of nivolumab & ipilimumab in MSI-H/dMMR mCRC

CheckMate 8HW: expanded analysis of nivolumab & ipilimumab in MSI-H/dMMR mCRC

Heinz-Josef Lenz, MD, FACP, University of Southern California, Los Angeles, CA, discusses expanded

CheckMate 8HW: Nivolumab + Ipilimumab Shows Durable PFS Benefit in MSI-H/dMMR CRC

CheckMate 8HW: Nivolumab + Ipilimumab Shows Durable PFS Benefit in MSI-H/dMMR CRC

Michael Foote, MD, Memorial Sloan Kettering Cancer Center, discusses the final results from the